CG Oncology (CGON) Projected to Post Quarterly Earnings on Friday

Posted by on Aug 5th, 2026

CG Oncology (NASDAQ:CGON – Get Free Report) is anticipated to announce its Q2 2026 results before the market opens on Friday, August 7th. Analysts expect the company to announce earnings of ($0.6642) per share and revenue of $0.3610 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 12:30 PM ET.

CG Oncology (NASDAQ:CGON – Get Free Report) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The firm had revenue of $1.08 million for the quarter, compared to the consensus estimate of $0.45 million. On average, analysts expect CG Oncology to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

CG Oncology Stock Performance

Shares of CGON stock opened at $71.40 on Wednesday. CG Oncology has a fifty-two week low of $23.65 and a fifty-two week high of $77.00. The stock’s fifty day moving average price is $66.35 and its two-hundred day moving average price is $63.59. The company has a market cap of $6.30 billion, a PE ratio of -30.64 and a beta of 0.23.

Insider Activity

In other CG Oncology news, Director Leonard E. Post sold 5,000 shares of CG Oncology stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $70.00, for a total value of $350,000.00. Following the sale, the director owned 5,000 shares of the company’s stock, valued at approximately $350,000. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director James Mulay sold 24,165 shares of the business’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $75.16, for a total transaction of $1,816,241.40. Following the completion of the transaction, the director owned 24,165 shares in the company, valued at approximately $1,816,241.40. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 37,129 shares of company stock valued at $2,663,817 in the last ninety days. 4.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On CG Oncology

Institutional investors and hedge funds have recently bought and sold shares of the company. Picton Mahoney Asset Management purchased a new position in shares of CG Oncology during the 4th quarter valued at $118,000. Tower Research Capital LLC TRC increased its stake in shares of CG Oncology by 159.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,982 shares of the company’s stock worth $182,000 after purchasing an additional 4,288 shares in the last quarter. Sei Investments Co. bought a new stake in shares of CG Oncology in the second quarter valued at approximately $209,000. Verition Fund Management LLC bought a new stake in shares of CG Oncology in the third quarter valued at approximately $221,000. Finally, Man Group plc purchased a new stake in shares of CG Oncology during the 2nd quarter valued at approximately $224,000. 26.56% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on CGON shares. Wall Street Zen downgraded shares of CG Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a research note on Friday, July 17th. Wedbush raised their price target on shares of CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of CG Oncology in a research report on Wednesday, July 29th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $82.00 price target (up from $77.00) on shares of CG Oncology in a research report on Thursday, May 14th. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.73.

View Our Latest Analysis on CGON

CG Oncology Company Profile

(Get Free Report)

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.

Read More

Earnings History for CG Oncology (NASDAQ:CGON)

Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.